Subscribe
shutterstock_1424448053_aaron-schwartz
Aaron-Schwartz / Shutterstock.com
21 October 2019Big PharmaSaman Javed

US committee votes in favour of Pelosi’s drug pricing plan

The US House Committee on Energy & Commerce has voted to advance a drug pricing plan which would lower the cost of many prescription drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Industry dubs Pelosi’s drug pricing plan ‘extreme’
20 September 2019   The Biotechnology Innovation Organization has claimed that if the drug pricing plan unveiled by US House of Representatives Speaker Nancy Pelosi yesterday, September 19, becomes law, it will upend the US’s ability to lead the world in biomedical innovation.


Editor's picks

Americas
LSPN finalists revealed for first-ever US awards
3 March 2025

Editor's picks

Americas
LSPN finalists revealed for first-ever US awards
3 March 2025
Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025

More on this story

Americas
Industry dubs Pelosi’s drug pricing plan ‘extreme’
20 September 2019   The Biotechnology Innovation Organization has claimed that if the drug pricing plan unveiled by US House of Representatives Speaker Nancy Pelosi yesterday, September 19, becomes law, it will upend the US’s ability to lead the world in biomedical innovation.

More on this story

Americas
Industry dubs Pelosi’s drug pricing plan ‘extreme’
20 September 2019   The Biotechnology Innovation Organization has claimed that if the drug pricing plan unveiled by US House of Representatives Speaker Nancy Pelosi yesterday, September 19, becomes law, it will upend the US’s ability to lead the world in biomedical innovation.

More features

Teva can’t revive Orange book inhaler battle at Fed Circ
Jones Day adds experienced patent litigators from Weil
WIPR Leaders revamps selection process for 2025 edition
La Prairie accused of stealing caviar biotech for luxury skincare line
LSPN finalists revealed for first-ever US awards
Amy Candido to head IP litigation team at Simpson Thacher
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
The rise of weight loss drugs: Regulators tighten up